Stockholm - Delayed Quote SEK

EQL Pharma AB (EQL.ST)

Compare
64.40 -2.40 (-3.59%)
At close: 5:22 PM GMT+2
Loading Chart for EQL.ST
DELL
  • Previous Close 66.80
  • Open 66.80
  • Bid 63.40 x --
  • Ask 64.40 x --
  • Day's Range 63.40 - 67.00
  • 52 Week Range 49.20 - 68.20
  • Volume 19,715
  • Avg. Volume 11,822
  • Market Cap (intraday) 1.872B
  • Beta (5Y Monthly) 0.73
  • PE Ratio (TTM) 72.36
  • EPS (TTM) 0.89
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

www.eqlpharma.com

22

Full Time Employees

March 31

Fiscal Year Ends

Recent News: EQL.ST

View More

Performance Overview: EQL.ST

Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

EQL.ST
11.03%
OMX Stockholm 30 Index
0.01%

1-Year Return

EQL.ST
11.03%
OMX Stockholm 30 Index
0.01%

3-Year Return

EQL.ST
11.03%
OMX Stockholm 30 Index
0.01%

5-Year Return

EQL.ST
11.03%
OMX Stockholm 30 Index
0.01%

Compare To: EQL.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EQL.ST

View More

Valuation Measures

Annual
As of 10/21/2024
  • Market Cap

    1.94B

  • Enterprise Value

    2.08B

  • Trailing P/E

    75.06

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.68

  • Price/Book (mrq)

    10.32

  • Enterprise Value/Revenue

    7.15

  • Enterprise Value/EBITDA

    51.85

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.04%

  • Return on Assets (ttm)

    7.18%

  • Return on Equity (ttm)

    15.04%

  • Revenue (ttm)

    290.75M

  • Net Income Avi to Common (ttm)

    26.29M

  • Diluted EPS (ttm)

    0.89

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.37M

  • Total Debt/Equity (mrq)

    74.66%

  • Levered Free Cash Flow (ttm)

    -97.01M

Research Analysis: EQL.ST

View More

Company Insights: EQL.ST

Research Reports: EQL.ST

View More

People Also Watch